Mechanism of Action
GPR10 and UHR1 Receptor Activation
PrRP binds GPR10 (also called UHR1) with high affinity, activating Gq and Gi signaling pathways. GPR10 is expressed in hypothalamic nuclei (DMN, PVN, NTS) involved in food intake and energy expenditure. PrRP also binds neuropeptide FF receptor 2 (NPFFR2) at higher concentrations, linking it to pain modulation and opioid system interactions.
Satiety and Energy Balance
Central PrRP administration suppresses food intake and reduces body weight in rodents. PrRP neurons in the NTS receive visceral satiety signals from the gut (via vagal afferents) and relay them to appetite-regulating hypothalamic circuits. PrRP knockout mice show increased food intake and late-onset obesity, establishing it as a physiological satiety signal.
Research Summary
Appetite Suppression and Obesity
PreclinicalICV PrRP reduces food intake acutely in rodents. Chronic peripheral administration requires lipidated or conjugated analogs for CNS access; lipidated PrRP analogs show sustained weight loss and improved metabolic parameters in DIO mice. PrRP-GLP-1 fusion peptides are under development as dual-action metabolic therapeutics.
Stress Response
PreclinicalPrRP neurons are activated by stressors and stimulate the HPA axis. Central PrRP increases CRH release and acth/" class="wiki-internal-link">ACTH secretion. GPR10 knockout mice show blunted stress-induced corticosterone responses. This stress-energy balance integration positions PrRP as a bridge between metabolic state and stress responsiveness.
Pain Modulation
PreclinicalPrRP activates NPFFR2 receptors involved in pain modulation and opioid anti-analgesia. Central PrRP increases pain thresholds in some models while potentiating opioid tolerance in others. The dual GPR10/NPFFR2 pharmacology complicates the pain profile and is an active research area.
Calculate your Prolactin-Releasing Peptide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Appetite suppression (rodent) | 1-10 nmol ICV | Single injection | Intracerebroventricular |
| Weight loss (lipidated analog, rodent) | 1-5 mg/kg SC | Daily or every 3 days | Subcutaneous |
| HPA axis activation (rodent) | 1-5 nmol ICV | Single injection | Intracerebroventricular |
No human clinical trials. Native PrRP has poor CNS penetration when given peripherally. Lipidated and conjugated analogs are the focus of current research.
Interactions
Safety Profile
No human safety data. In rodents, systemic PrRP causes hypophagia and weight loss at effective doses. HPA activation is a concern for chronic administration. The NPFFR2-mediated opioid interaction could affect pain management if developed as a therapeutic. No commercial product exists; PrRP is a research tool.
References
- [1]Hinuma S, et al. A prolactin-releasing peptide in the brain. Nature. 1998;393(6682):272-276.
- [2]Takayanagi Y, Onaka T. Roles of prolactin-releasing peptide and RFamide related peptides in the control of stress and food intake. FEBS J. 2010;277(21):4536-4543.
- [3]Maixnerova J, et al. Lipidized analogs of prolactin-releasing peptide: study of their metabolic stability, ability to decrease food intake and the levels of selected appetite-modulating peptides. PLoS One. 2011;6(12):e28233.